Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Leishmaniasis

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...

Antiprotozoal Agents

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...

Modified-Release Drug Delivery Systems: Overview

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Enhanced diagnostic tools for visceral leishmaniasis using kinase based antigens in Brazilian human and canine samples.

Scientific reports·2026

Same author

Functional and phenotypic analysis of CD4 T cell dynamics in peripheral blood of human visceral leishmaniasis patients confers increased frequencies of CD25 expressing regulatory T cells that contribute to disease pathogenesis.

Frontiers in immunology·2025

Same author

A Dual-Action Liposome-Peptide Formulation Synergistically Counteracts A Gain-of-Function p53 Mutant.

bioRxiv : the preprint server for biology·2025

Same author

A dual-action liposome-peptide formulation synergistically counteracts a gain-of-function p53 mutant.

Journal of liposome research·2025

Same author

Evaluation of <i>Leishmania</i> homolog of activated C kinase (LACK) of <i>Leishmania donovani</i> in comparison to glycoprotein 63 as a vaccine candidate against visceral leishmaniasis.

Microbiology spectrum·2025

Same author

Recombinant Leishmania-activated C kinase as a novel antigenic candidate for immuno-diagnosis of visceral leishmaniasis occurring in India and Brazil.

Infectious diseases of poverty·2025

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

Recent developments in leishmaniasis vaccine delivery systems.

Sudipta Bhowmick¹, Nahid Ali

¹Indian Institute of Chemical Biology, Infectious Diseases and Immunology Division, 4, Raja S.C. Mullick Road, Kolkata, India.

Expert Opinion on Drug Delivery

|July 2, 2008

Summary

This summary is machine-generated.

Developing effective vaccines against leishmaniasis is crucial. Cationic liposomes show promise as delivery systems for new leishmaniasis vaccines, enhancing their potential.

More Related Videos

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Published on: April 21, 2023

Related Experiment Videos

Last Updated: Jul 4, 2026

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

In vivo Imaging of Transgenic Leishmania Parasites in a Live Host

Published on: July 27, 2010

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Development of Leishmania Species Strains with Constitutive Expression of eGFP

Published on: April 21, 2023

Area of Science:

Immunology
Vaccinology
Parasitology

Background:

Recovery from Leishmania infection confers immunity, suggesting vaccination potential.
Newer vaccines (recombinant proteins, DNA) show limited immunogenicity.
Leishmaniasis control necessitates improved vaccine strategies.

Purpose of the Study:

Address the urgent need for novel and enhanced vaccine adjuvants.
Review current adjuvants and delivery systems for leishmaniasis vaccines.
Identify promising strategies for effective leishmaniasis vaccine development.

Main Methods:

Classified adjuvants into immunostimulatory agents and delivery systems.
Highlighted the role of delivery systems in transporting antigens and adjuvants to antigen-presenting cells (APCs).
Reviewed various adjuvants, delivery systems, and their combinations for leishmaniasis vaccine research.

Main Results:

Adjuvants are broadly categorized by their mechanism of action.
Vaccine delivery systems are essential for efficient antigen and adjuvant transport to APCs.
Combinations of adjuvants and delivery systems are explored for enhanced vaccine efficacy.

Conclusions:

Cationic liposomes demonstrate significant potential as effective delivery systems.
Further development of cationic liposomes could lead to a viable leishmaniasis vaccine.
Optimizing delivery systems is key to overcoming challenges in leishmaniasis vaccine development.